

**BAKER BOTTS** LLP*Fax receipt will not be confirmed by phone unless requested.*30 ROCKEFELLER PLAZA  
NEW YORK, NEW YORK  
10112-4498  
212.408-2500  
FAX 212.408-2501  
www.bakerbotts.comAUSTIN  
BAKU  
DALLAS  
HOUSTON  
LONDON  
NEW YORK  
RIYADH  
WASHINGTONFROM Rochelle K. Seide, Ph.D.  
DATE November 20, 2003  
PAGES 5 (including cover)VOICE NO. 212.408.2626  
FAX NO. 212.259.2426  
RETURN TO Evelyn MederoTO Examiner Samuel Liu  
United States Patent & Trademark OfficeFAX NO. 703.872.9306  
VOICE NO. 703.306.3483**OFFICIAL**

## MESSAGE

RECEIVED  
CENTRAL FAX CENTER

NOV 20 2003

Re: U.S. Patent Application No.: 09/785,059  
by Montelaro *et al.*, filed February 16, 2001  
for "VIRUS DERIVED ANTIMICROBIAL PEPTIDES"  
Our File: A33577-072396.0217

Dear Examiner Liu:

Please immediately deliver the attached PTO Form 1449 (considered on August 15, 2002) to Examiner Samuel Liu in Group Art Unit 1653 for entry in the above-identified application.

Best regards.

Rochelle K. Seide, Ph.D.

## NY02:464398, 1 Notice of Confidentiality

The information contained in and transmitted with this facsimile is: 1. Subject to the Attorney-client Privilege; 2. Attorney Work Product; or 3. Confidential. It is intended only for the individual or entity designated above. You are hereby notified that any dissemination, distribution, copying, or use of or reliance upon the information contained in and transmitted with this facsimile by or to anyone other than the recipient designated above by the sender is unauthorized and strictly prohibited. If you have received this facsimile in error, please notify Baker Botts L.L.P. by telephone at 212.408-2500 immediately. Any facsimile erroneously transmitted to you should be immediately returned to the sender by U.S. Mail or, if authorization is granted by the sender, destroyed.

If you do not receive all pages, please call: 212.408-2500 for assistance.



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)	Atty. Docket No. 072396.0217 (A33577)	Serial No. 09/785,059
	Applicant Montelaro et al.	
	Filing Date February 16, 2001	Group To Be Assigned

## U.S. PATENT DOCUMENTS


Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.
SWL	1 5 9 4 5 5 0 7	08/31/99	Montelaro et al.			
SWL	7 5 7 1 4 5 7 7	02/03/98	Montelaro et al.			

## FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Subclass	Translation Yes No


## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

SWL	3	File, TM. "Overview of Resistance in the 1990s", <i>Chest</i> , 115:3S-8S. March 1999 Supplement
SWL	4	Friedrich et al., "Salt-Resistant Alpha-Helical Cationic Antimicrobial Peptides", <i>Antimicrobial Agents and Chemotherapy</i> , 43: 1542-1548, 1999
SWL	5	Hancock, R.E., "Host Defence (Cationic) Peptides: What Is Their Future Clinical Potential?", <i>Drugs</i> , 57: 469-473, Adis International Limited, 1999.
SWL	6	Scott, Yan, and Hancock, "Biological Properties of Structurally Related $\alpha$ -Helical Cationic Antimicrobial Peptides", <i>Infection &amp; Immunity</i> , 67: 2005-2009, Apr. 1999

Examiner 	Date Considered 8-15-2002
---	------------------------------

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY02:324574.1



Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.  
072396.0217 (A33577)

Serial No.  
09/785,059

Applicant  
Montelaro et al.

Filing Date  
February 16, 2001

Group  
To Be Assigned

swl	7	Tencza et al., "Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization", <i>Journal of Antimicrobial Chemotherapy</i> , <b>44</b> : 33-41, 1999
swl	8	Beary et al., "Interruption of T-cell signal transduction by lentivirus lytic peptides from HIV-1 transmembrane protein", <i>Journal of Peptide Research</i> , <b>51</b> : 75-79, 1998
swl	9	Hwang and Vogel, "Structure-function relationships of antimicrobial peptides", <i>Biochem. Cell Biol.</i> , <b>76</b> : 235-246, 1998
swl	10	Comardelle et al., "A Synthetic Peptide Corresponding to the Carboxy Terminus of Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Induces Alterations in the Ionic Permeability of <i>Xenopus laevis</i> Oocytes", <i>AIDS Research &amp; Human Retroviruses</i> , <b>13</b> : No. 17, pp.1525-1532, 1997.
swl	11	Ganz and Lehrer, "Antimicrobial peptides of leukocytes", <i>Current Opinion in Hematology</i> , <b>4</b> : 53-58, 1997
swl	12	Tencza et al., "Novel Antimicrobial Peptides Derived from Human Immunodeficiency Virus Type 1 and Other Lentivirus Transmembrane Proteins", <i>Antimicrobial Agents &amp; Chemotherapy</i> , <b>41</b> : 2394-2398, 1997
swl	13	Tencza et al., "Calmodulin-Binding Function of LLP Segments from the HIV Type 1 Transmembrane Protein Is Conserved among Natural Sequence Variants", <i>AIDS Research &amp; Human Retroviruses</i> , <b>13</b> : No. 3, 263-269, 1997
swl	14	Arroyo et al., "Membrane Permeabilization by Different Regions of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein gp41", <i>J. Virol.</i> <b>69</b> : 4095-4102, 1995.
swl	15	Tencza et al., "Effect of Amino Acid Substitutions on Calmodulin Binding and Cytolytic Properties of the LLP-1 Peptide Segment of Human Immunodeficiency Virus Type 1 Transmembrane Protein", <i>Journal of Virology</i> , <b>69</b> : 5199-5202, 1995

Examiner		Date Considered	8-15-2002
----------	--	-----------------	-----------


\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY02:324574.1



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)	Atty. Docket No. 072396.0217 (A33577)	Serial No. 09/785,059
	Applicant Montelaro et al.	
	Filing Date February 16, 2001	Group To Be Assigned

SWL	16	Yuan et al., "Characterization of the Calmodulin Binding Domain of SIV Transmembrane Glycoprotein by NMR and CD Spectroscopy", <i>Biochemistry</i> , <b>34</b> : 10690-10696, 1995.
SWL	17	Zanetti, Gennaro and Romeo, "Cathelicidins: a novel protein family with a common propepion and a variable C-terminal antimicrobial domain", <i>FEBS Letters</i> , <b>374</b> :1-5, 1995
SWL	18	Merrifield et al., "Design and synthesis of antimicrobial peptides", Antimicrobial Peptides, Ciba Foundation Symposium, , 5-6, 1994.
SWL	19	Moore et al., "Preliminary Experimental Anticancer Activity of Cecropins", <i>Peptide Research</i> , <b>7</b> :265-269, 1994.
SWL	20	Miller et al., "Identification of a Calmodulin-Binding and Inhibitory Peptide Domain in the HIV-1 Transmembrane Glycoprotein", 1993, <i>AIDS Reseach and Human Retroviruses</i> , <b>9</b> : 1057-1066.
SWL	21	Miller et al., "Alterations in Cell Membrane Permeability by the Lentivirus Lytic Peptide (LLP-1) of HIV-1 Transmembrane Protein", <i>Virology</i> , <b>196</b> : 89-1000, 1993
SWL	22	Blondelie et al., "Design of Model Amphipathic Peptides Having Potent Anitmicrobial Activities", <i>Biochemistry</i> , <b>31</b> :12688-12694, 1992
SWL	23	Srinivas et al., "Membrane Interactions of Synthetic Peptides Corresponding to Amphopathic Helical Segments of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein", <i>Journal of Biological Chemistry</i> , <b>267</b> :7121-7127, 1992
SWL	24	Wild et al., ""A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition", <i>Proc. Natl. Acad. Sci. USA</i> , <b>89</b> : 10537-10541, 1992.
SWL	25	Fontenot et al., "A Survey of Potential Problems and Quality Control in Peptide Synthesis by the Fluorenylmethoxycarbonyl Procedure", <i>Peptide Research</i> , <b>4</b> :19-25, 1991

Examiner		Date Considered	8-15-2002
----------	---	-----------------	-----------

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY02:324574.1



Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. 072396.0217 (A33577)	Serial No. 09/785,059
	Applicant Montelaro et al.	
	Filing Date February 16, 2001	Group To Be Assigned

26	Miller et al., "A Structural Correlation Between Lentivirus Transmembrane Proteins and Natural Cytolytic Peptides", <i>AIDS Research &amp; Human Retroviruses</i> , 7:511-519, 1991.
27	Eisenberg and Wesson, "The Most Highly Amphiphilic $\alpha$ -Helices Include Two Amino Acid Segments in Human Immunodeficiency Virus Glycoprotein 41", <i>Biopolymers</i> , 29: 171-177, 1990
28	Eisenberg et al., "The hydrophobic moment detects periodicity in protein hydrophobicity", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 81:140-144, 1984
29	Chou et al., "Prediction of The Secondary Structure of Proteins From Their Amino Acid Sequence", <i>Adv Enz Relat Areas Mol Bio</i> , 47: 45-146, 1978.
30	Garnier et al., "Analysis of the Accuracy and Implications of Simple Methods for Predicting the Secondary Structure of Globular Proteins", <i>J. Mol. Biol.</i> , 120: 97-120, 1978

Examiner	Date Considered
----------	-----------------

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NY02:324574-1